Targeting RAS to overcome FLT3 AML drug resistance
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
Elevated levels of trimethylamine N-oxide levels were a stronger indicator of CKD risk than the well-known risk factors.
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
IFNβ could be developed into a new therapy, following an improved understanding of how innate immunity affects the brain during chronic HIV infection.
Researchers have gained a deeper understanding of the neural biology of obesity, which could offer potential drug targets.
Researchers have presented new findings that offer potential pathways to arrest critical steps toward the accumulation of mutant tau.
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.